MAP2K1 is an inclusion criterion in 18 clinical trials for malignant solid tumor, of which 15 are open and 3 are closed. Of the trials that contain MAP2K1 status and malignant solid tumor as inclusion criteria, 9 are phase 1 (8 open), 1 is phase 1/phase 2 (1 open), and 8 are phase 2 (6 open) [4].

MAP2K1 is an inclusion criterion in 7 clinical trials for non-small cell lung carcinoma, of which 6 are open and 1 is closed. Of the trials that contain MAP2K1 status and non-small cell lung carcinoma as inclusion criteria, 5 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [4].

MAP2K1 is an inclusion criterion in 6 clinical trials for melanoma, of which 5 are open and 1 is closed. Of the trials that contain MAP2K1 status and melanoma as inclusion criteria, 2 are phase 1 (2 open), 3 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [4].

MAP2K1 is an inclusion criterion in 3 clinical trials for non-hodgkin lymphoma, of which 2 are open and 1 is closed. Of the trials that contain MAP2K1 status and non-hodgkin lymphoma as inclusion criteria, 3 are phase 2 (2 open) [4].

MAP2K1 is an inclusion criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain MAP2K1 status and acute myeloid leukemia as inclusion criteria, 2 are phase 2 (2 open) [4].

MAP2K1 is an inclusion criterion in 2 clinical trials for colorectal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MAP2K1 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

MAP2K1 is an inclusion criterion in 2 clinical trials for glioma, of which 2 are open and 0 are closed. Of the trials that contain MAP2K1 status and glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

MAP2K1 is an inclusion criterion in 2 clinical trials for histiocytic and dendritic cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain MAP2K1 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 2 are phase 2 (1 open) [4].

MAP2K1 is an inclusion criterion in 2 clinical trials for low grade glioma, of which 2 are open and 0 are closed. Of the trials that contain MAP2K1 status and low grade glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

MAP2K1 is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MAP2K1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

MAP2K1 is an inclusion criterion in 2 clinical trials for thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain MAP2K1 status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

MAP2K1 is an inclusion criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MAP2K1 is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MAP2K1 is an inclusion criterion in 1 clinical trial for cancer, of which 0 are open and 1 is closed. Of the trial that contains MAP2K1 status and cancer as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

MAP2K1 is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MAP2K1 is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

MAP2K1 is an inclusion criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MAP2K1 is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MAP2K1 is an inclusion criterion in 1 clinical trial for dysembryoplastic neuroepithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and dysembryoplastic neuroepithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MAP2K1 is an inclusion criterion in 1 clinical trial for embryonal rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and embryonal rhabdomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MAP2K1 is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MAP2K1 is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and esophageal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MAP2K1 is an inclusion criterion in 1 clinical trial for gangliocytoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and gangliocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MAP2K1 is an inclusion criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MAP2K1 is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MAP2K1 is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MAP2K1 is an inclusion criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MAP2K1 is an inclusion criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MAP2K1 is an inclusion criterion in 1 clinical trial for mucosal melanoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and mucosal melanoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MAP2K1 is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [4].

MAP2K1 is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [4].

MAP2K1 is an inclusion criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 2 (1 open) [4].

MAP2K1 is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

MAP2K1 is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MAP2K1 is an inclusion criterion in 1 clinical trial for neurofibromatosis type 1, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and neurofibromatosis type 1 as inclusion criteria, 1 is phase 2 (1 open) [4].

MAP2K1 is an inclusion criterion in 1 clinical trial for neuronal and mixed neuronal-glial tumors, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and neuronal and mixed neuronal-glial tumors as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MAP2K1 is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

MAP2K1 is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MAP2K1 is an inclusion criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MAP2K1 is an inclusion criterion in 1 clinical trial for pilomyxoid astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and pilomyxoid astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MAP2K1 is an inclusion criterion in 1 clinical trial for poorly differentiated thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and poorly differentiated thyroid gland carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

MAP2K1 is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and renal cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MAP2K1 is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MAP2K1 is an inclusion criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and schwannoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MAP2K1 is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MAP2K1 is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

MAP2K1 is an inclusion criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].